OPKO HEALTH, INC. OPK revenue by segment, product and geography
In its fiscal year ending 2025-12-31, OPKO HEALTH, INC. reported revenue across 4 products and services; the largest, Service, was $370M (-23.0% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Service$370Mshare n/a-23.0% yoy
- Product$157Mshare n/a+1.2% yoy
- Transfer Of Intellectual Property And Other$79.7Mshare n/a+3.0% yoy
- Rayaldee$59.4Mshare n/a-14.3% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$436M71.9%-20.2% yoy
- CL$62.4M10.3%-4.1% yoy
- Ireland$51.4M8.5%+6.2% yoy
- Spain$26.7M4.4%+8.5% yoy
- Mexico$25.5M4.2%+6.9% yoy
- Other countries$4.27M0.7%+36.8% yoy
- IL$522K0.1%-70.5% yoy
Members sum to the consolidated $607M for this period.
- Service$74.5Mshare n/a-26.3% yoy
- Intellectual Property And Other$46.1Mshare n/a+207.3% yoy
- Transfer Of Intellectual Property And Other$46.1Mshare n/a+208.0% yoy
- Product$42.9Mshare n/a+5.4% yoy
- Rayaldee$14.3Mshare n/a-1.8% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.